HOUSTON, June 22, 2018 /PRNewswire/
-- Cellenkos™ and The University Of Texas Health Science Center at
Houston today announce a research collaboration for
application of cord blood-derived regulatory T cells (CK0801) as
adoptive therapy for treatment of neuroinflammatory disorders. The
first condition to be studied will include Guillain-Barré Syndrome
(GBS), a rare disorder in which the body's immune system attacks
part of the peripheral nervous system. Patients with GBS who
have not responded to standard therapies will be evaluated for
CK0801 therapy.
Guillain-Barré syndrome can be a devastating disorder because of
its sudden and unexpected onset. Current treatment options are only
partly effective and a significant proportion of Guillain-Barré
syndrome patients do not respond to frontline therapies. There are
no evidence-based treatment recommendations for these unresponsive
patients. "This is an exciting step towards finding an effective
treatment for Guillain-Barré syndrome," said Dr Kazim Sheikh, principal investigator for the
Cellenkos, Inc. neuroinflammation research collaboration.
"Innovative approaches and application of novel cell therapy for
replacing and repairing the defective immune system of patients
suffering from debilitating diseases such as GBS can prove to be an
important step in our endeavor to find effective treatment for this
disease. CK0801 works to replace and replenish the defective
regulatory T cells and blocks the constant damage to the
neurological system as a result of uncontrolled inflammatory
signals. Such an interruption of the neural insult loop can allow
for their recovery".
About Guillain-Barré syndrome
Guillain-Barré
syndrome is a rare disorder that destroys the protective covering
of the peripheral nerves (myelin sheath), preventing the nerves
from transmitting signals to the brain. The exact cause of
Guillain-Barré syndrome is unknown. But it is often preceded by an
infectious illness such as a respiratory infection or the stomach
flu. The first symptoms of this disorder include varying degrees of
weakness or tingling sensations in the legs. In many instances the
symmetrical weakness and abnormal sensations spread to the arms and
upper body. These symptoms can increase in intensity until certain
muscles cannot be used at all and, when severe, the person is
almost totally paralyzed. Guillain-Barré syndrome can affect
anyone. It can strike at any age and both men and women are equally
prone to the disorder. There are no known cures for
Guillain-Barré syndrome.
About The University Of Texas Health
Science Center At Houston
Established in 1972 by The
University of Texas System Board of
Regents, The University of Texas Health
Science Center at Houston (UTHealth) is Houston's Health University and Texas' resource for health care education,
innovation, scientific discovery and excellence in patient
care. As a comprehensive health science university, the
mission of The University of Texas Health
Science Center at Houston is to educate health science
professionals, discover and translate advances in the biomedical
and social sciences, and model the best practices in clinical care
and public health.
About CK0801
CK0801 is a first-in-class, cord
blood-derived T-regulatory cellular product, developed using
Cellenkos' proprietary manufacturing platform, which overcomes
immune dysfunction by inhibiting key regulators of inflammation.
CK0801 contains healthy and robust regulatory T cells derived
from donor cord blood units and adoptive therapy with CK0801 has
the potential to replenish the immune system and impact patient
care by providing novel, non-pharmacologic options. CK0801
will be manufactured at Cellenkos' FDA registered manufacturing
facility located in Houston, Texas.
About Cellenkos, Inc.
Cellenkos, Inc. is an
early stage biotechnology company that focuses on cord
blood-derived T regulatory cellular therapies for the treatment of
autoimmune diseases and inflammatory disorders.
For more information, please
visit www.cellenkosinc.com.
CONTACT:
Erin Horne
832-962-7628
erin.horne@cellenkosinc.com
Cellenkos™. All rights reserved. Cellenkos and
Cellenkos logo are trademarks of Cellenkos, Inc.
View original content with
multimedia:http://www.prnewswire.com/news-releases/cellenkos-inc-announces-neuroinflammation-research-collaboration-with-the-university-of-texas-health-science-center-at-houston-300671145.html
SOURCE Cellenkos, Inc.